Oncotelic Holdings Inc.
2025 Annual Report – Key Highlights for Investors

Introduction

Oncotelic Holdings Inc. has released its Form 10-K Annual Report for the fiscal year ended December 31, 2025. This summary provides investors with a comprehensive, detailed analysis of all price-sensitive and essential information contained within the report.

Key Corporate Information

• Company Name: Oncotelic Holdings Inc.
• Fiscal Year Ended: December 31, 2025
• CIK: 0000908259
• Common Stock Outstanding as of April 14, 2026: 444,197,032 shares
• Public Float as of June 30, 2025: \$9,108,801 (based on OTC Market closing price)
• Par Value of Common Stock: \$0.01 per share
• Exchange Listing: None (OTC Market)

Filing Status and Regulatory Compliance

• Oncotelic is a non-accelerated filer and qualifies as a smaller reporting company.
• The company is not a well-known seasoned issuer and not an emerging growth company.
• Not a shell company as of the report date.
• Compliant with all Section 13 or 15(d) filing requirements in the last 12 months.
• All required Interactive Data Files have been submitted electronically as per Regulation S-T.
• No restatements or error corrections were made to previously issued financial statements.
• No requirement for recovery analysis under SEC rule 240.10D-1(b) regarding incentive-based compensation clawbacks.
• No documents incorporated by reference.

Capital Structure and Securities

• Common Stock: Registered under Section 12(g) of the Exchange Act.
• Preferred Stock: Series A Convertible Preferred Stock is referenced in the filing, indicating complex capital and potential conversion features which may impact dilution and share value in the future.
• No securities listed on a national securities exchange as of the date of filing.

Governance and Internal Controls

• No auditor attestation on internal controls over financial reporting under Section 404(b) of the Sarbanes-Oxley Act.
• Disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not included and will not be included in future filings or proxy statements.

Board and Executive Information

• Details about directors, executive officers, and governance practices are included in the full filing. Investors should review these for information on leadership and oversight.

Shareholder and Financial Data

• Aggregate Market Value of Non-Affiliate Voting Stock (as of June 30, 2025): \$9,108,801
• Outstanding Shares (as of April 14, 2026): 444,197,032

The increase in outstanding shares and the low public float relative to the number of shares suggest potential dilution risks, which investors should monitor closely.

Items of Potential Price Sensitivity

1. Capital Structure and Dilution Risk

The large number of outstanding shares (444 million+) and the relatively small public float (\$9.1 million) could signal significant potential dilution, especially in the context of convertible preferred stock and convertible notes mentioned throughout the document. Any conversion of preferred or debt securities could further increase share count, potentially applying downward pressure on the stock price.

2. No Listing on a National Exchange

Oncotelic’s shares are not listed on any national securities exchange, which may affect liquidity, investor access, and institutional interest. This is a critical factor for valuation and potential volatility.

3. Filing and Compliance Status

The company is compliant with all SEC reporting requirements. There are no financial restatements, no auditor attestation on internal controls, and no indication of material weaknesses disclosed. However, investors should monitor future filings for any changes regarding auditor involvement or restatements, as these can be price-sensitive events.

Corporate Governance and Executive Compensation

• Detailed information on executive compensation, related party transactions, and beneficial ownership is included in the report. Investors are encouraged to review Item 12 and 13 for related party risks and the potential impact on governance and share value.

Other Noteworthy Elements

• The document provides a full table of contents, including sections on business operations, patents, regulatory matters, risk factors, legal proceedings, market information, management’s discussion and analysis, and financial statements.

Conclusion for Investors

Key Takeaways:

• Oncotelic Holdings remains a non-accelerated, smaller reporting company with no national exchange listing, which may limit liquidity and institutional visibility.
• A significant number of outstanding shares and a low public float could indicate substantial future dilution risk, especially if convertible securities are exercised.
• No restatements, error corrections, or auditor attestation issues identified in this filing, indicating a stable reporting environment as of the fiscal year end.
• Investors should monitor future disclosures for any change in capital structure, governance, or regulatory status, as these will be the most likely catalysts for share price movement.

No immediate price-sensitive events such as major legal proceedings, restatements, or auditor resignations are disclosed in this annual report. The most material issue for investors is the ongoing potential for dilution and the company’s continued OTC Market status.

Disclaimer: This summary is for informational purposes only and does not constitute investment advice. Investors should review the full Form 10-K and consult with professional advisors before making any investment decisions. The author assumes no liability for decisions based on this article.

View Oncotelic Therapeutics, Inc. Historical chart here